Perspective Therapeutics' (CATX) "Outperform" Rating Reiterated at Royal Bank of Canada

Perspective Therapeutics (NYSE:CATX - Get Free Report)'s stock had its "outperform" rating reiterated by Royal Bank of Canada in a research report issued on Tuesday,Benzinga reports. They presently have a $16.00 price target on the stock. Royal Bank of Canada's price objective suggests a potential upside of 400.00% from the stock's previous close.

A number of other analysts have also recently weighed in on the stock. Oppenheimer decreased their target price on shares of Perspective Therapeutics from $22.00 to $16.00 and set an "outperform" rating on the stock in a research note on Friday, November 22nd. UBS Group assumed coverage on Perspective Therapeutics in a report on Thursday, October 24th. They issued a "buy" rating and a $20.00 price objective for the company. Bank of America downgraded Perspective Therapeutics from a "buy" rating to a "neutral" rating and lowered their target price for the stock from $24.00 to $5.00 in a report on Monday, November 25th. Truist Financial began coverage on Perspective Therapeutics in a research note on Wednesday, September 25th. They issued a "buy" rating and a $21.00 price objective for the company. Finally, Wedbush reaffirmed an "outperform" rating and issued a $11.00 price objective on shares of Perspective Therapeutics in a research note on Monday. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the company. According to data from MarketBeat, Perspective Therapeutics presently has an average rating of "Moderate Buy" and an average price target of $15.14.

Perspective Therapeutics Stock Performance

Shares of CATX stock traded down $0.20 during midday trading on Tuesday, hitting $3.20. 1,539,702 shares of the company were exchanged, compared to its average volume of 1,168,050. Perspective Therapeutics has a 52 week low of $2.70 and a 52 week high of $19.05. The firm's 50 day moving average price is $4.98 and its two-hundred day moving average price is $10.20.

Perspective Therapeutics (NYSE:CATX - Get Free Report) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.21) EPS for the quarter, meeting the consensus estimate of ($0.21). Perspective Therapeutics had a negative net margin of 4,096.66% and a negative return on equity of 27.40%. The business had revenue of $0.37 million for the quarter. On average, sell-side analysts predict that Perspective Therapeutics will post -0.88 earnings per share for the current year.

Insider Buying and Selling at Perspective Therapeutics

In other news, CFO Jonathan Robert Hunt purchased 12,829 shares of the stock in a transaction dated Monday, November 25th. The shares were purchased at an average cost of $3.82 per share, with a total value of $49,006.78. Following the completion of the acquisition, the chief financial officer now owns 48,800 shares in the company, valued at $186,416. This represents a 35.66 % increase in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, Director Heidi Henson purchased 25,975 shares of the business's stock in a transaction on Wednesday, December 4th. The stock was purchased at an average cost of $3.85 per share, for a total transaction of $100,003.75. Following the acquisition, the director now owns 25,975 shares in the company, valued at approximately $100,003.75. The trade was a ∞ increase in their ownership of the stock. The disclosure for this purchase can be found here. Over the last quarter, insiders have purchased 67,570 shares of company stock valued at $256,789. 3.52% of the stock is currently owned by corporate insiders.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in CATX. nVerses Capital LLC acquired a new position in Perspective Therapeutics during the third quarter worth about $57,000. US Bancorp DE increased its stake in Perspective Therapeutics by 142.7% in the 3rd quarter. US Bancorp DE now owns 6,576 shares of the company's stock valued at $88,000 after buying an additional 3,866 shares during the period. Intech Investment Management LLC purchased a new position in shares of Perspective Therapeutics in the third quarter valued at $137,000. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Perspective Therapeutics during the third quarter worth $152,000. Finally, Los Angeles Capital Management LLC acquired a new stake in Perspective Therapeutics during the third quarter worth about $153,000. 54.66% of the stock is currently owned by institutional investors.

About Perspective Therapeutics

Perspective Therapeutics, Inc, together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma.